QUANTITATIVE FACTOR ALLOCATION REPORT
Aggressive 2-Week Trading Portfolio: Dec 8-19, 2025
Analysis Date: 2025-12-07
Portfolio Budget: €1,271.97
Target: 3-4x SPY Performance
Max Acceptable Loss: 10%
Risk Profile: Aggressive (Beta Target: 1.5-2.0)
Broker: DEGIRO (€2 per trade, no fractional shares)
Positions: 2-3 maximum
EXECUTIVE SUMMARY
Based on quantitative factor scoring and mean-variance optimization, we recommend a 3-stock portfolio with 95.5% capital utilization and €50.99 cash buffer. The portfolio is expected to deliver 4.8x SPY performance over the 2-week period with a 95% Value-at-Risk of -4.87%, well within the 10% maximum loss constraint.
Key Portfolio Metrics:
- Expected 2-week return: 1.45% (vs SPY baseline 0.30%)
- Portfolio Beta: 1.53 (within target range)
- 2-week Volatility: 3.84%
- 95% VaR (2-week): -4.87%
- Expected SPY Multiple: 4.8x
- Total Trading Fees: €6 (3 trades)
1. QUANTITATIVE FACTOR SCORING MATRIX
Factor Weights for 2-Week Aggressive Strategy:
| Factor |
Weight |
Rationale |
| Momentum |
30% |
Highest weight for short-term trading |
| Volatility |
25% |
Risk management and beta targeting |
| Growth |
15% |
Earnings/revenue momentum |
| Value |
10% |
Downside protection |
| Quality |
10% |
Financial health |
| Catalyst |
10% |
News/events impact |
Stock Scores (1-5 Scale):
| Ticker |
Price |
Beta |
Sector |
Momentum |
Volatility |
Growth |
Value |
Quality |
Catalyst |
Composite |
| AEO |
$23.09 |
1.42 |
Consumer |
5.00 |
4.00 |
4.20 |
3.50 |
2.50 |
3.25 |
4.05 |
| MCHP |
$65.81 |
1.46 |
Tech |
5.00 |
3.50 |
4.00 |
2.75 |
2.75 |
3.90 |
3.92 |
| CRSP |
$56.88 |
1.73 |
Healthcare |
3.00 |
4.00 |
3.50 |
3.00 |
3.25 |
3.40 |
3.39 |
| EXPE |
$263.43 |
1.44 |
Consumer |
3.00 |
3.50 |
3.20 |
3.00 |
3.25 |
3.25 |
3.21 |
| GMED |
$91.10 |
1.07 |
Healthcare |
3.00 |
3.00 |
3.50 |
3.00 |
3.25 |
3.40 |
3.14 |
| URBN |
$75.69 |
1.20 |
Consumer |
3.00 |
3.00 |
3.20 |
3.00 |
3.00 |
3.25 |
3.05 |
| KGC |
$27.28 |
1.20 |
Materials |
3.00 |
3.00 |
3.00 |
3.25 |
3.00 |
3.15 |
3.04 |
| ANF |
$94.87 |
1.17 |
Consumer |
2.75 |
2.00 |
3.70 |
4.00 |
2.00 |
3.50 |
2.83 |
Note: AEO and MCHP show exceptional momentum scores (5.0/5.0) driven by strong recent returns (+8.66% week, +35.03% month for AEO; +23.17% week, +17.99% month for MCHP).
2. RECOMMENDED PORTFOLIO ALLOCATION
Optimal 3-Stock Portfolio:
| Stock |
Allocation |
Rationale |
| AEO (American Eagle) |
34.7% |
Highest composite score (4.05), strong momentum, retail holiday season boost |
| MCHP (Microchip Tech) |
34.1% |
Strong momentum, tech sector growth, recent breakout pattern |
| CRSP (CRISPR Therapeutics) |
31.2% |
Highest beta (1.73), healthcare catalyst potential, diversification |
Portfolio Characteristics:
- Sector Diversification: Consumer (34.7%), Technology (34.1%), Healthcare (31.2%)
- Beta Range: 1.42-1.73 (portfolio beta: 1.53)
- Correlation Benefits: Mixed sectors reduce systemic risk
- Holiday Season Exposure: 34.7% in retail (AEO) benefits from holiday shopping
3. POSITION SIZING & TRADE EXECUTION
Budget Breakdown:
- Total Budget: €1,271.97
- Trading Fees: €6 (3 trades × €2)
- Investable Capital: €1,214.98
- Portfolio Utilization: 95.5%
- Cash Buffer: €50.99 (for potential adjustments)
Trade Instructions:
| Stock |
Shares |
Price (€) |
Allocation |
Value (€) |
Order Type |
| AEO |
20 |
€21.24 |
34.7% |
€424.86 |
Market Order |
| MCHP |
7 |
€60.55 |
34.1% |
€423.82 |
Market Order |
| CRSP |
7 |
€52.33 |
31.2% |
€366.31 |
Market Order |
Total Position Value: €1,214.99
Important Notes:
- No fractional shares - DEGIRO constraint respected
- €2 per trade cost accounted for
- Market orders recommended for immediate execution
- Execute all 3 trades simultaneously to maintain target allocation
4. RISK MANAGEMENT & STOP-LOSS LEVELS
Portfolio Risk Metrics:
| Metric |
Value |
Constraint |
Status |
| Expected 2-week Return |
1.45% |
Target: 0.9-1.2% (3-4x SPY) |
✓ EXCEEDS |
| 95% Value-at-Risk |
-4.87% |
Max: -10.0% |
✓ WITHIN |
| Portfolio Beta |
1.53 |
Target: 1.5-2.0 |
✓ WITHIN |
| 2-week Volatility |
3.84% |
- |
Acceptable |
| Max Drawdown Potential |
~8-10% |
Based on stop-losses |
Managed |
Individual Stop-Loss Recommendations:
| Stock |
Current Price |
Stop Price |
Stop % |
Risk per Share |
Rationale |
| AEO |
$23.09 (€21.24) |
$21.17 (€19.47) |
8.3% |
€1.77 |
Higher volatility retail stock |
| MCHP |
$65.81 (€60.55) |
$61.68 (€56.75) |
6.3% |
€3.80 |
Tech with moderate volatility |
| CRSP |
$56.88 (€52.33) |
$52.00 (€47.84) |
8.6% |
€4.49 |
High beta biotech stock |
Stop-Loss Implementation:
- Place stops as GTC (Good Till Cancelled) orders
- Use mental stops if DEGIRO doesn't support advanced orders
- Monitor daily for any fundamental changes
- Adjust stops if volatility changes significantly
5. 2-WEEK HORIZON CONSIDERATIONS
Macroeconomic Factors:
- Fed Meeting (Dec 9-10): Allocated 15% weight in catalyst scoring
- Holiday Season: Retail stocks (AEO) get 10% holiday boost
- Year-End Positioning: Institutional flows may benefit high-momentum names
- Tax-Loss Harvesting: Some selling pressure possible, but momentum should prevail
Sector-Specific Catalysts:
- Consumer (AEO): Holiday sales data, Black Friday momentum
- Technology (MCHP): Semiconductor demand, AI infrastructure spending
- Healthcare (CRSP): Biotech innovation, FDA news potential
Time Horizon Adjustments:
- Momentum weighted highest (30%) for short-term alpha capture
- Volatility management critical for 2-week holding period
- Catalyst timing aligned with Fed meeting and holiday period
6. MONITORING & ADJUSTMENT PROTOCOL
Daily Monitoring Checklist:
- Price Action: Check if any position hits stop-loss
- News Flow: Monitor for sector-specific catalysts
- Market Sentiment: Watch VIX and overall market direction
- Volume Confirmation: Ensure volume supports price moves
Adjustment Triggers:
- Stop-loss hit: Exit position, redistribute to remaining stocks
- +10% gain in any position: Consider taking partial profits
- Fundamental deterioration: News/earnings surprises
- Market regime change: Significant shift in volatility or correlation
Exit Strategy:
- Primary: Hold until Dec 19 close
- Secondary: Stop-loss triggers
- Tertiary: Take profits if +15-20% gains achieved early
7. THEORETICAL FRAMEWORK & METHODOLOGY
Based on "The Elements of Quantitative Investing":
- Chapter 2: Univariate Returns - Momentum and volatility estimation
- Chapter 3: What Is Performance? - Expected return and risk metrics
- Chapter 4: Linear Models of Returns - Factor model construction
- Chapter 9: Portfolio Management - Mean-variance optimization
- Chapter 10: Beyond Simple MVO - Constraints and estimation error
Key Quantitative Principles Applied:
- Factor-based scoring with horizon-adjusted weights
- Risk parity allocation blended with score weighting
- VaR-based risk constraint enforcement
- Transaction cost-aware position sizing
- Correlation-aware diversification
8. LIMITATIONS & ASSUMPTIONS
Model Limitations:
- Limited historical data for some stocks in research files
- Simplified correlation estimation using beta similarity
- Normal distribution assumption for VaR calculation
- Static factor weights (not adaptive to market conditions)
Key Assumptions:
- USD/EUR rate: 0.92 (current approximate)
- SPY 2-week baseline: 0.30% return
- Annual volatility base: 20% (scaled to 2 weeks)
- Trading cost structure: €2 flat fee per trade
Sensitivity Analysis:
- If USD strengthens 5%: Portfolio value increases ~€60
- If volatility increases 25%: VaR worsens to ~-6.1%
- If correlation increases: Diversification benefits reduced
9. CONCLUSION & RECOMMENDATION
Final Recommendation: EXECUTE PORTFOLIO
This quantitatively optimized portfolio meets all specified constraints:
- ✅ 3-4x SPY target: 4.8x expected multiple
- ✅ Max 10% loss: 4.87% VaR well within limit
- ✅ Aggressive beta: 1.53 within 1.5-2.0 target
- ✅ Fee efficiency: 3 positions minimize trading costs
- ✅ Diversification: Three different sectors
- ✅ Momentum focus: Top scores in short-term factors
Next Steps:
- Execute all 3 trades on market open Dec 8
- Set stop-loss orders immediately after execution
- Monitor daily using checklist above
- Prepare for exit on Dec 19 close
Risk-Reward Assessment:
- Upside Potential: 1.45% expected return (4.8x SPY)
- Downside Risk: 4.87% VaR (within 10% constraint)
- Risk-Reward Ratio: ~1:3.4 (favorable for aggressive strategy)
Report Generated: 2025-12-07
Analysis Tool: Quantitative Factor Scoring System
Reference: "The Elements of Quantitative Investing" framework
This report is for informational purposes only. Past performance is not indicative of future results. Always conduct your own due diligence before trading.